PAR. SP, page-654

Given PAR have rewarded prior MPS trial subjects with free iPPS for 5 years post their involvement in the trials, I dare say our safety data is exceptional (as always). Talk about belief in your drug molecule.

I am as perplexed as the next, as to why the timelines are over promised and under delivered on. But (for an absolutely wild guess) my guess is the 5-9 age stratum may have required some additional work once the dataset was pulled together, particularly if administering the dose earlier in the disease progression has a larger effect on the quality of life on these patients…. here is hoping!

There’s a positive spin as we live in the land uncertainty. Weird…. And Sheesh…..!